CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu(The University of Texas MD Anderson Cancer Center), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Aarthi Balasubramanyam(Materials Systems (United States)), Ling Li(Zhengzhou University), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Qin Huang(City Of Hope National Medical Center), Attilio Orazi(Texas Tech University), Wei‐Min Liu(Roche (Switzerland)), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Weiyun Z. Ai(University of California, San Francisco), Kristy L. Richards(University of North Carolina at Chapel Hill), April Chiu(Mayo Clinic), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Lin Wu(Materials Systems (United States)), Jooryung Huh(Asan Medical Center), Mingzhi Zhang(Soochow University), Yong Li(Baylor College of Medicine), Li Zhang(Chongqing Emergency Medical Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Xiaoying Zhao(Second Affiliated Hospital of Zhejiang University), Jane N. Winter(Northwestern University)
Blood
January 24, 2013
Cited by 246


Related Papers